In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.

@article{Lee2000InVP,
  title={In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.},
  author={Chong Sik Lee and A. Samii and Vesna Sossi and Thomas J. Ruth and Michael Schulzer and James E. Holden and James Wudel and Pramod Kr. Pal and Ra{\'u}l de la Fuente-Fern{\'a}ndez and Donald B. Calne and A. Jon Stoessl},
  journal={Annals of neurology},
  year={2000},
  volume={47 4},
  pages={493-503}
}
Clinical symptoms of Parkinson's disease (PD) do not manifest until dopamine (DA) neuronal loss reaches a symptomatic threshold. To explore the mechanisms of functional compensation that occur in presynaptic DA nerve terminals in PD, we compared striatal positron emission tomographic (PET) measurements by using [11C]dihydrotetrabenazine ([11C]DTBZ; labeling the vesicular monoamine transporter type 2), [11C]methylphenidate (labeling the plasma membrane DA transporter), and [18F]dopa (reflecting… CONTINUE READING